Impact of body size on first‐line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy

• DOI: 10.1111/hel.12788
• Publication Date: 2021-02-14T16:12:40Z
• Authors: Hiroyuki Eto; Sho Suzuki; Chika Kusano; Hisatomo Ikehara; Ryoji Ichijima; Hirotaka Ito; Koichi Kawabe; Masashi Kawamura; Yoshioki Yoda; Moriyasu Nakahara; Takuji Gotoda
• Keywords: Male; Sulfonamides; Helicobacter pylori; Amoxicillin; Proton Pump Inhibitors; Anti-Bacterial Agents; Helicobacter Infections; 3. Good health; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Clarithromycin; Body Size; Humans; Drug Therapy, Combination; Female; Pyrroles; Retrospective Studies

Abstract Background As a first‐line therapy for Helicobacter pylori , dual with vonoprazan and amoxicillin (VA‐dual) provides an eradication rate similar to that of vonoprazan‐based triple therapy. the factors associated H. VA‐dual are unknown,we investigated them in this study. Materials Methods Overall, 163 patients diagnosed infection received (vonoprazan 20 mg twice daily 750 7 d). The association between successful following patient clinical was analyzed: sex, age, height, weight, body surface area (BSA), mass index (BMI), history early gastric carcinoma peptic ulcer, comorbidity cirrhosis, alcohol consumption habit, smoking common use proton pump inhibitors, concomitant drugs substratesof cytochrome P450 (CYP) 3A4. post‐eradication adverse events analyzed retrospectively. Results Successful lower BSA (eradication rate: 90.8% <1.723 vs. 79.6% those ≥1.723; p = 0.045). incidence higher women than men (adverse events: 40.0% 19.4% men; 0.004). Conclusions small size patients. This may have be adjusted per size.